In this new video, the SPIOMET4HEALTH team looks back on the work carried out so far and shares the exciting progress of the clinical trial that could change the future of care for women with PCOS.
Polycystic Ovary Syndrome (PCOS) is one of the most common hormonal conditions in women, yet there is still no specific, approved treatment that targets its causes. Since 2021, the SPIOMET4HEALTH project has been working to change this reality.
Funded by the European Union, the project brings together research teams and hospitals from across Europe to investigate a new treatment designed to go beyond symptoms and address the roots of PCOS. SPIOMET4HEALTH aims to go beyond simply relieving symptoms: it seeks to understand and act on the underlying causes of the condition. By doing so, the project hopes to open new possibilities for their long-term health and well-being.
What has happened so far at SPIOMET4HEALTH?
The SPIOMET4HEALTH clinical trial has advanced thanks to the collaboration of multiple centres and professionals — from the study set-up to patient recruitment, supported by clinicians and awareness campaigns. Once included in the study, patients begin an 18-month journey: one year of treatment followed by six months of monitoring.
After completing recruitment and follow-up, the project is currently entering a decisive phase: the analysis of the clinical trial data. This stage is essential to ensure reliable, meaningful results that can show whether the SPIOMET treatment can truly make a difference for young women with PCOS.
Hear directly from the researchers and discover how SPIOMET4HEALTH is bringing science closer to women’s everyday lives!
The release of this video comes at a very special moment for SPIOMET4HEALTH. As we just closed this year’s PCOS Awareness Month and after recently meeting in Barcelona for our 4th General Assembly, the consortium looks back on how far we’ve come and the collaboration that continues to drive the project forward.
What is next?
The coming months will be crucial. Once the final data are analysed, the consortium will move towards sharing results and conclusions — a key step toward improving care for women with PCOS. As Lourdes Ibáñez, Project Coordinator at Sant Joan de Déu Hospital, explains in the video, if the hypothesis is confirmed and SPIOMET proves to normalise ovulation more effectively than placebo, the next goal will be to reach and help millions of women living with PCOS.
Follow our journey on social media and stay tuned for the next updates as SPIOMET4HEALTH moves forward toward new milestones in women’s health.
👉 Follow us on Instagram | Follow us on LinkedIn | Follow us on X